AQP4 and myeloid sarcoma: In a previous study, GFAP levels were also found to be higher in the CSF of AQP4-ab+NMOSD patients, compared with those in the CSF of MOGAD and MS patients, although the investigators used enzyme-linked immunosorbent assays rather than SIMOA to measure GFAP concentrations (31).